Kodiak Sciences Inc (KOD)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
KOD price, last 12 months
Key stats
- Previous close
- $33.22
- Open
- $33.10
- Day range
- $31.00 – $41.82
- 52-week range
- $10.94 – $47.84
- Volume
- 2.1M
- Avg volume (20 days)
- 848.9K
- Market cap
- $2.0B
Performance
Technicals and fundamentals
About Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $2.0B